Pharmacological prevention of atrial electrical remodeling represents a potential novel therapeutic target for atrial fibrillation, though its development remains in its infancy.
SHINAGAWA, K., et al .: Pharmacological Prevention of Atrial Tachycardia Induced Atrial Remodeling as a Potential Therapeutic Strategy. Atrial fibrillation (AF) is the most common cardiac arrhythmia requiring medical therapy, and present treatment modalities are inadequate. Over the past few years, we have learned a great deal about the phenomenon of electrical remodeling, by which rapid atrial activation leads to changes in atrial electrical properties that promote AF initiation and maintenance. This knowledge opens up the possibility that electrical remodeling may itself be a novel therapeutic target in AF. The present paper reviews what is known about the basic mechanisms of atrial electrical remodeling and then discusses the experimental and clinical evidence that remodeling can be prevented by drug therapy. Despite great potential value, the development of pharmacological interventions to prevent atrial electrical remodeling is still in its infancy. (PACE 2003; 26:752–764)
Shinagawa et al. (Sat,) conducted a review in Atrial fibrillation. Pharmacological interventions was evaluated. Pharmacological prevention of atrial electrical remodeling represents a potential novel therapeutic target for atrial fibrillation, though its development remains in its infancy.